Author Archives: Andrew Sandford

Bringing Biologic Products to Market Faster By Partnering with a Single Services Provider from Development Through Commercial Supply

by

Andrew Sandford, vice president of business development, Catalent Biologics Catalent feels strongly about “Patients First.” The core of the company’s mission is to “enhance and improve the lives of your patients.” Bringing a new drug to market is expensive, costing about US$2.6 billion per drug. It takes an average of 12 years from drug discovery to final approval, with only 1 in 5,000 products ultimately approved by the Food and Drug Administration. The expense, risk, and long timelines of drug…

August 21, 2018

Making the Correct Outsourcing Decisions: BPI Theater Panelists at BIO 2016 Discuss Current and Future Needs for Contract Services

by , , , , and

Outsourcing has become a critical part of the industry in general and will play a larger role as companies continue to seek faster and more cost-effective routes to market. On Wednesday 8 June 2016, Gil Roth (president of the Pharma and Biopharma Outsourcing Association, PBOA) chaired a lunchtime roundtable titled “Making the Correct Outsourcing Decisions.” Roth’s association is a nonprofit trade group that represents CMOs and CDMOs through work with Congress and the FDA, with a focus on intra-industry issues.…

September 15, 2016